DiaSorin (OTCMKTS:DSRLF) Rating Increased to Hold at Zacks Research

DiaSorin (OTCMKTS:DSRLF) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

DSRLF has been the topic of a number of other reports. BNP Paribas Exane upgraded shares of DiaSorin to a “neutral” rating in a research note on Wednesday, January 28th. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, DiaSorin presently has an average rating of “Hold”.

DiaSorin Stock Performance

OTCMKTS DSRLF opened at $67.00 on Tuesday. The firm’s 50 day moving average price is $71.57 and its 200-day moving average price is $75.91. DiaSorin has a 52-week low of $66.50 and a 52-week high of $112.30.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.